Deerfield Management Company, L.P. (Series C) Cullinan Oncology, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,860,839 shares of CGEM stock, worth $33.7 Million. This represents 0.74% of its overall portfolio holdings.
Number of Shares
3,860,839
Previous 3,379,399
14.25%
Holding current value
$33.7 Million
Previous $41.2 Million
29.0%
% of portfolio
0.74%
Previous 1.02%
Shares
9 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$66.8 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$50.3 Million1.91% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$31 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.8 Million15.23% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.22MShares$28.1 Million9.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $399M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...